OKG Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
OXcan
9 Jan 2025
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
52North
6 Dec 2024
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
More venture news
- 12 Mar 2026
Combat MedicalCombat Medical raises a £2.6m Series A led by T&J Meyer Family Foundation for hard-to-treat bladder cancer
Series AHealth - 10 Mar 2026
OutpostOutpost unlocks £13m Series A led by Ribbit for cross-border payments and tax compliance infrastructure
Series AFintech - 4 Mar 2026
Shellworks raises £11m Series A led by Alter Equity for biodegradable packaging made from microbial fermentation
Series ASupply Chain
